Abstract
Aim:
To investigate possible pharmacological mechanisms underlying the antinociceptive effect of and tolerance to N-methyl-7α-[(R)-1-hydroxy-1-methyl-3-(thien-3-yl)-propyl]-6,14-endo-ethanotetrahydronororipavine (030418), a derivative of thienorphine.
Methods:
The binding affinity and efficacy of 030418 were determined using receptor binding and guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) assays in CHO-μ, CHO-κ, CHO-δ, and CHO-ORL1 cell membranes. The analgesic activity of and tolerance to 030418 were evaluated in thermal nociceptive tests in mice. The effects of 030418 on opioid receptors were further investigated using in vivo pharmacological antagonist blockade and in vitro tissue preparations.
Results:
The compound 030418 displayed high binding affinity to all subtypes of opioid receptors with Ki values in the nanomolar range. In [35S]GTPγS binding assay, the maximal stimulation of 030418 to μ-, κ-, δ-receptors and the ORL1 receptor was 89%, 86%, 67% and 91%, respectively. In hot-plate test, the antinociceptive effect of 030418 was more potent and longer than morphine. The nonselective opioid receptor antagonist naloxone could completely block 030418-induced antinociception, while both the μ-opioid receptor antagonist β-FNA and the κ-opioid receptor antagonist nor-BNI attenuated 030418-induced antinociception. In contrast, the ORL1 receptor antagonist J-113397 enhanced the antinociceptive effect of 030418. Additionally, chronic treatment with 030418 resulted in a dramatic development of tolerance that could not be effectively prevented by J-113397. In guinea pig ileum preparation, the existing action of 030418 could be removed with difficulty after prolonged washing.
Conclusion:
The compound 030418 is a novel agonist of opioid receptors with high efficiency, long-lasting effect and liability to tolerance, which may be closely correlated with the methyl group at the N17 position and the high hydrophobicity of the C7-thiophene group in its chemical structure.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1283–93.
Koob GF, Le Moal M . Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52–8.
Berger AC, Whistler JL . How to design an opioid drug that causes reduced tolerance and dependence. Ann Neurol 2010; 67: 559–69.
Bentley KW, Hardy DG . Novel analgesics and molecular rearrangements in the morphine-thebaine group. I. Ketones derived from 6,14-endo-ethenotetrahydrothebaine. J Am Chem Soc 1967; 89: 3267–73.
Bentley KW, Hardy DG . Novel analgesics and molecular rearrangements in the morphine-thebaine group. III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J Am Chem Soc 1967; 89: 3281–92.
Lewis JW, Husbands SM . The orvinols and related opioids — high affinity ligands with diverse efficacy profiles. Curr Pharm Des 2004; 10: 717–32.
Cowan A, Lewis JW, MacFarlane IR . Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60: 537–45.
Mello NK, Mendelson JH, Lukas SE, Gastfriend DR, Teoh SK, Holman BL . Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies. Harv Rev Psychiatry 1993; 1: 168–83.
Picard PR, Tramer MR, McQuay HJ, Moore RA . Analgesic efficacy of peripheral opioids (all except intra-articular): a qualitative systematic review of randomised controlled trials. Pain 1997; 72: 309–18.
Barnett PG, Rodgers JH, Bloch DA . A metaanalysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96: 683–90.
Park HS, Lee HY, Kim YH, Park JK, Zvartau EE, Lee H . A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability. Bioorg Med Chem Lett 2006; 16: 3609–13.
Rennison D, Neal AP, Cami-Kobeci G, Aceto MD, Martinez-Bermejo F, Lewis JW, et al. Cinnamoyl derivatives of 7α-aminomethyl-6,14-endoethanotetrahydrothebaine and 7α-aminomethyl-6,14-endoethanotetrahydrooripavine and related opioid ligands. J Med Chem 2007; 50: 5176–82.
Liu CH, Liu H, Han XY, Wu B, Zhong BH, Gong ZH . Synthesis and characterization of thienorphine and its glucuronide conjugate. Synth Commun 2005; 35: 701–10.
Zhao WL, Gong ZH, Liang JH . A new buprenorphine analogy, thienorphine, inhibits morphine-induced behavioral sensitization in mice. Acta Pharmacol Sin 2004; 25: 1413–8.
Yu G, Yue YJ, Cui MX, Gong ZH . Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine. J Pharmacol Exp Ther 2006; 318: 282–7.
Li JX, Becker GL, Traynor JR, Gong ZH, France CP . Thienorphine: receptor binding and behavioral effects in rhesus monkeys. J Pharmacol Exp Ther 2006; 321: 227–36.
Yu G, Liu YS, Yan LD, Wen Q, Gong ZH . Structure-activity relationships analysis of thienorphine and its derivatives. Yao Xue Xue Bao 2009; 44: 726–30.
Loew GH, Berkowitz DS . Intramolecular hydrogen bonding and conformational studies of bridged thebaine and oripavine opiate narcotic agonists and antagonists. J Med Chem 1979; 22: 603–7.
Sebastian A, Bidlack JM, Jiang Q, Deecher D, Teitler M, Glick SD, et al. 14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydro-morphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem 1993; 36: 3154–60.
Zhu J, Luo LY, Chen C, Liu-Chen LY . Activation of the cloned human kappa-opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 1997; 282: 676–68.
Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.
D'Amour FE, Smith DL . A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 72: 74–9.
Eddy NB, Leimbach D . Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 1953; 107: 385–93.
Horan P, Taylor J, Yamamura HI, Porreca F . Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 1992; 260: 1237–43.
Craft RM, Henley SR, Haaseth RC, Hruby VJ, Porreca F . Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration. J Pharmacol Exp Ther 1995; 275: 1535–42.
Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003; 23: 10331–7.
Wu N, Lu XQ, Yan HT, Su RB, Wang JF, Liu Y, et al. Aquaporin 4 deficiency modulates morphine pharmacological actions. Neurosci Lett 2008; 448: 221–5.
Paton WD, Vizi ES . The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea-pig ileum longitudinal muscle strip. Br J Pharmacol 1969; 35: 10–28.
Bliss CI . Statistics in biology. New York: McGraw-Hill Book Company; 1967.
Ueda H, Inoue M, Takeshima H, Iwasawa Y . Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. J Neurosci 2000; 20: 7640–7.
Chung S, Pohl S, Zeng J, Civelli O, Reinscheid RK . Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 2006; 318: 262–7.
Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, et al. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 2007; 320: 934–43.
Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, et al. Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 2008; 153: 609–19.
Aceto MD, Harris LS, Bowman ER . Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity. Eur J Pharmacol 1997; 338: 215–23.
Boas RA, Villiger JW . Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 1985; 57: 192–6.
Neilan CL, Husbands SM, Breeden S, Ko MC, Aceto MD, Lewis JW, et al. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur J Pharmacol 2004; 499: 107–16.
Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD, et al. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol 2005; 509: 117–25.
Pasternak GW . Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993; 16: 1–18.
Kieffer BL, Evans CJ . Opioid tolerance — in search of the holy grail. Cell 2002; 108: 587–90.
Hambrook JM, Rance MJ . The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW, editor. Opiates and endogenous opioid peptides. Amsterdam: Elsevier; 1976. p 295–301.
Woolf PJ, Linderman JJ . Untangling ligand induced activation and desensitization of G-protein coupled receptors. Biophys J 2003; 84: 3–13.
Acknowledgements
This work was supported by the National High Technology Research and Development Program of China (No 2005AA233040) and the National S&T Major Project of Original New Drug Research of China (No 2009ZXJ09004-079). We acknowledge Dr Bo-hua ZHONG and his group for supplying samples of 030418 and thienorphine for these experiments. We also thank Dr Zheng YONG and Dr Yan GAO for excellent expert technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wen, Q., Yu, G., Li, Yl. et al. Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418. Acta Pharmacol Sin 32, 1215–1224 (2011). https://doi.org/10.1038/aps.2011.83
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2011.83
Keywords
This article is cited by
-
Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation
Acta Pharmacologica Sinica (2015)
